Evotec SE EVO
NASDAQ EVO
$1.81 -0.01 (-0.55%)
At close: Sep 9, 2026 · 4:00 PM EDT

Evotec SE (EVO) Equity Income (2009 - 2023)

Evotec SE's (EVO) quarterly Equity Income came in at $7.8 million in Q3 2023, up 276.08% quarter-over-quarter from -$4.4 million in Q2 2023.

Analysis

Evotec SE (EVO) Equity Income (2009 - 2023) Analysis & Trends

Evotec SE has disclosed Equity Income across 3 years of filings, most recently posting $7.8 million for Q3 2023.

  • In Q3 2023, Equity Income changed N/A year-over-year to $7.8 million; the TTM figure through Aug 2023 stood at $14.8 million (changed N/A YoY), while the FY2022 annual figure was $8.0 million, changed N/A from the prior year.
  • Equity Income came in at $7.8 million for Q3 2023 at Evotec SE, up from -$4.4 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $7.8 million in Q3 2023 to a low of -$4.4 million in Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Iqvia Holdings 42.77 Bn 40.69 Bn 1.44 Bn 17.00 Mn
2 Medpace Holdings 16.50 Bn 16.00 Bn 201.64 Mn -
3 Charles River Laboratories International 13.37 Bn 13.18 Bn 452.07 Mn -
4 Icon 12.49 Bn 11.56 Bn 479.29 Mn -
5 Fortrea Holdings 1.58 Bn 1.42 Bn 139.20 Mn -
6 Evotec SE 642.83 Mn 216.96 Mn - -
7 Ginkgo Bioworks Holdings 422.55 Mn 338.02 Mn 18.44 Mn -4.67 Mn
8 Champions Oncology 69.16 Mn 69.16 Mn 7.03 Mn -
9 MindWalk Holdings 59.83 Mn 51.55 Mn 1.82 Mn -
10 VivoSim Labs 1.45 Mn 1.45 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Aug 29, 2023 7.78 Mn
Jun 30, 2023 -4.42 Mn
Dec 31, 2022 7.78 Mn
Sep 30, 2022 3.64 Mn
Jun 30, 2022 -4.37 Mn
Dec 31, 2009 -826,971.17
Jun 30, 2009 -62,635.82
Mar 31, 2009 19,616.00